Services · Regulatory & Ethics Consultancy

Navigating SAHPRA
and Ethics Submissions
with Confidence

Alpha CR Solutions manages the full regulatory and ethics submission lifecycle, from CTA preparation through SAHPRA approval, IRB and IEC submissions, to ongoing compliance.

Submission Status
Pre-submission packDOC
SAHPRA CTA lodgedCTA
Ethics / IEC reviewIEC
ApprovalAPPROVED

Accelerating Approval.
Protecting Compliance.

Navigating the South African regulatory and ethics landscape demands more than form-filling. It requires deep institutional knowledge, established relationships with health authorities, and a rigorous quality framework.

Our team integrates directly into your study operations, managing submissions to the South African Health Products Regulatory Authority (SAHPRA) and ethics committees registered with the National Health Research Ethics Council (NHREC).

Whether you are an emerging biotech conducting your first Phase I trial in South Africa, or a global sponsor expanding into Africa, we tailor our regulatory strategy to your timeline, budget, and therapeutic area.

Get in Touch

Core Capabilities

  • SAHPRA Clinical Trial Applications (CTA)
  • Category D medicine licence applications, amendments and renewals
  • Ethics submissions to NHREC-registered IRBs
  • Site IEC submissions and maintenance
  • ICF development and review
  • Regulatory strategy and gap analysis
  • Source Data Review (SDR) methodology
  • ICH E6(R3) GCP Training & certification
  • Annual progress reports and amendments
  • IMPD and Investigator Brochure review
  • CRA services across therapeutic areas

The Path from Protocol to Patient

Alpha CR Solutions manages every phase of the South African regulatory and ethics approval process, giving you a single point of accountability from submission to site activation.

1

ICF Development

Informed consent documents prepared to SAHPRA and ICH standards.

2

SAHPRA CTA Submission

Full CTA compiled including IMPD, IB and protocol synopsis.

3

IRB & IEC Submissions

Parallel submissions to NHREC IRBs and site IECs.

4

Dual Approval

Coordinating SAHPRA and ethics approvals simultaneously.

5

Site Initiation

GCP training, SDR setup and SIV support.

6

Ongoing Compliance

Amendments, annual reports and safety notifications.

Regulatory & Ethics
Consultancy Services

Comprehensive support across the full spectrum of South African clinical trial regulatory requirements.

SAHPRA Regulatory Submissions

End-to-end management of all submissions to the South African Health Products Regulatory Authority.

  • Clinical Trial Application (CTA) preparation and submission
  • Protocol amendments and substantial modifications
  • Annual Progress Reports (APRs) and safety updates
  • IMPD review and Investigator Brochure gap analysis
  • Regulatory strategy and timeline planning
  • Query response and health authority liaison
  • End of trial notifications and study closure
  • Category D medicine licence applications, amendments and renewals (DL01 to DL03)

Ethics Committee Submissions

Full lifecycle management of IRB and IEC submissions in compliance with NHREC requirements.

  • NHREC-registered central IRB submissions
  • Site-level IEC submissions and annual renewals
  • ICF development, localisation and version control
  • Ethics committee query management
  • Protocol amendment submissions to ethics
  • Annual continuing review submissions
  • SAE and SUSAR reporting to ethics committees

CRA & Site Management

Experienced CRAs supporting sites from qualification through close-out to ICH E6(R3) standards.

  • Site qualification and selection visits (SQV)
  • Site initiation visits (SIV)
  • Routine monitoring visits (RMV)
  • Source data verification and SDR
  • Essential document review and TMF
  • Risk-based monitoring support
  • Site close-out visits (COV)

Submissions We Manage

Direct experience managing submissions across South African and international regulatory frameworks.

🇿🇦

SAHPRA

South African Health Products Regulatory Authority

  • Clinical Trial Applications (CTA)
  • Protocol amendments and annual reports
  • IMPD and IB submissions
  • Safety notifications and deviations
  • End of trial notifications
  • Category D licence applications, amendments and renewals (section 22C(1)(b))
🏛️

NHREC IRBs

National Health Research Ethics Council

  • Central IRB initial submissions
  • Annual continuing reviews
  • ICF review and version management
  • Protocol deviation reporting
  • SAE and SUSAR reporting
🏥

Site IECs

Institutional Ethics Committees

  • Site-specific ethics submissions
  • Multi-site IEC coordination
  • Local document localisation
  • Site-level query management
  • Ethics relationship management

Category D Medicine
Licence Applications

Category D is SAHPRA's category for complementary medicines. Companies that manufacture, import, export, wholesale or distribute them are licensed by SAHPRA under section 22C(1)(b) of the Medicines and Related Substances Act, 1965. We prepare and submit new applications, amendments and renewals for you. See SAHPRA's complementary medicines guidance.

New licence applications

DL01: Manufacture, import or export licence

For manufacturers of Category D complementary medicines, covering manufacture, import and export. SAHPRA's form is titled "Licence to manufacture, import or export Complementary Medicines (Category D)".

DL02: Import or export licence

For companies that import or export Category D complementary medicines. SAHPRA's form is titled "Licence to import or export Complementary Medicines (Category D)".

DL03: Wholesale or distribution licence

For companies that act as a wholesaler of, or distribute, Category D complementary medicines. SAHPRA's form is titled "Licence to act as a wholesaler of or distribute Complementary Medicines (Category D)".

Amendments and renewals

DA01 and DA02: Amendments

Changes to an existing Category D licence. DA01 is the "Amendment of existing Category D licence" and includes the option to upload only a product list showing deleted or new medicines. DA02 is the product list for an existing section 22C(1)(b) licence that already states Category D medicines. Holders of manufacture, import, export, wholesale and distribution licences can use both.

DR01, DR02 and DR03: Renewals

Renewal applications for existing licences. DR01 renews a manufacture, import or export licence, DR02 an import or export licence, and DR03 a wholesale or distribution licence.

We prepare and submit your application, amendment or renewal, respond to SAHPRA's queries and liaise with the authority on your behalf.

Discuss your licence application

Ready to move your trial forward?

Let Alpha CR Solutions manage the regulatory and ethics complexity, so you can focus on the science.

Contact Our Team →